Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Jan 22;34(3):563–571. doi: 10.1007/s10067-014-2857-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2015

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

PMC Copyright notice

Fig. 1 — Effectiveness at week 24. a ACR20/50/70/90 responses. b DAS28, CDAI, and SDAI responses. c Change from baseline in DAS28, CDAI, and SDAI. d Change from baseline in swollen joint count (SJC) and tender joint count (TJC). a p values were calculated by logistic regression analysis adjusted for previous treatment (DMARD-IR/TNFi-IR [previous TNFi use/recent TNFi use]) and baseline DAS28. Nonresponder imputation was performed for patients who withdrew or for whom responses were missing. b Hatched lines represent moderate EULAR response or low disease activity. EULAR good response: DAS28 ≤ 3.2 at week 24 and change of >−1.2. EULAR moderate response: DAS28 ≤ 3.2 at week 24 and change of <−0.6 to ≥−1.2 or <−1.2; DAS28 > 3.2 to ≤5.1 at week 24 and change of <1.2. DAS28: low disease activity (LDA), ≥2.6 to 3.2; remission, <2.6. CDAI: LDA, >2.8 to ≤10; remission, ≤2.8. SDAI: LDA, >3.3 to ≤11; remission, ≤3.3. p values calculated by logistic regression analysis adjusted for previous treatment (DMARD-IR/TNFi-IR [previous TNFi use/recent TNFi use]) and baseline DAS28, CDAI, or SDAI, as applicable. c TCZ monotherapy in DMARD-IR patients, n = 66; TCZ monotherapy in TNFi-IR patients, n = 173; TCZ + DMARDs in DMARD-IR patients, n = 910; TCZ + DMARDs in TNFi-IR patients, n = 532. p values were calculated by Wilcoxon rank-sum test and compare TCZ monotherapy and TCZ combination therapy (disregarding the DMARD-IR-TNFi-IR split). d TCZ monotherapy in DMARD-IR patients, n = 66; TCZ monotherapy in TNFi-IR patients, n = 173; TCZ + DMARDs in DMARD-IR patients, n = 910; TCZ + DMARDs in TNFi-IR patients, n = 532; p values were calculated by Wilcoxon rank-sum test and compare TCZ monotherapy and TCZ combination therapy (disregarding the DMARD-IR-TNFi-IR split)

Fig. 1 — Effectiveness at week 24. a ACR20/50/70/90 responses. b DAS28, CDAI, and SDAI responses. c Change from baseline in DAS28, CDAI, and SDAI. d Change from baseline in swollen joint count (SJC) and tender joint count (TJC). a p values were calculated by logistic regression analysis adjusted for previous treatment (DMARD-IR/TNFi-IR [previous TNFi use/recent TNFi use]) and baseline DAS28. Nonresponder imputation was performed for patients who withdrew or for whom responses were missing. b Hatched lines represent moderate EULAR response or low disease activity. EULAR good response: DAS28 ≤ 3.2 at week 24 and change of >−1.2. EULAR moderate response: DAS28 ≤ 3.2 at week 24 and change of <−0.6 to ≥−1.2 or <−1.2; DAS28 > 3.2 to ≤5.1 at week 24 and change of <1.2. DAS28: low disease activity (LDA), ≥2.6 to 3.2; remission, <2.6. CDAI: LDA, >2.8 to ≤10; remission, ≤2.8. SDAI: LDA, >3.3 to ≤11; remission, ≤3.3. p values calculated by logistic regression analysis adjusted for previous treatment (DMARD-IR/TNFi-IR [previous TNFi use/recent TNFi use]) and baseline DAS28, CDAI, or SDAI, as applicable. c TCZ monotherapy in DMARD-IR patients, n = 66; TCZ monotherapy in TNFi-IR patients, n = 173; TCZ + DMARDs in DMARD-IR patients, n = 910; TCZ + DMARDs in TNFi-IR patients, n = 532. p values were calculated by Wilcoxon rank-sum test and compare TCZ monotherapy and TCZ combination therapy (disregarding the DMARD-IR-TNFi-IR split). d TCZ monotherapy in DMARD-IR patients, n = 66; TCZ monotherapy in TNFi-IR patients, n = 173; TCZ + DMARDs in DMARD-IR patients, n = 910; TCZ + DMARDs in TNFi-IR patients, n = 532; p values were calculated by Wilcoxon rank-sum test and compare TCZ monotherapy and TCZ combination therapy (disregarding the DMARD-IR-TNFi-IR split)